Global Leading Market Research Publisher QYResearch announces the release of its latest report “Influenza A/B Virus Antigen Detection Kits – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Influenza A/B Virus Antigen Detection Kits market, including market size, share, demand, industry development status, and forecasts for the next few years.
The Influenza A/B Virus Antigen Detection Kits market represents a critical segment within the global in-vitro diagnostics (IVD) industry, playing a pivotal role in infectious disease screening, epidemiological surveillance, and frontline clinical decision-making. As global healthcare systems continue to strengthen early detection capabilities for respiratory infections, influenza antigen testing has become an essential diagnostic tool across hospitals, public health agencies, and increasingly, home-based self-testing environments.
Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6115573/influenza-a-b-virus-antigen-detection-kits
From a market valuation perspective, the global Influenza A/B Virus Antigen Detection Kits market was estimated to be worth approximately US$ 1,226 million in 2025 and is projected to reach US$ 1,699 million by 2032, expanding at a CAGR of 4.8% during the forecast period of 2026–2032. This steady growth trajectory reflects persistent seasonal influenza prevalence, enhanced global public health surveillance infrastructure, and increasing consumer acceptance of rapid diagnostic testing, particularly in decentralized and home-care settings.
In terms of product definition, Influenza A/B virus antigen detection kits are in-vitro diagnostic (IVD) products designed for the rapid identification of influenza A and B viral antigens in respiratory samples. These kits primarily utilize immunochromatographic lateral flow assays or fluorescent immunoassay technologies, enabling clinicians and users to obtain results within minutes to half an hour. Compared with traditional laboratory-based PCR testing, antigen detection kits provide a faster, more accessible, and cost-efficient diagnostic alternative, particularly suitable for large-scale screening scenarios.
The technological foundation of this market is built upon a complex biological and materials science value chain. Upstream components include high-affinity monoclonal and polyclonal antibodies, antigen controls, colloidal gold or fluorescent labeling materials, nitrocellulose membranes, absorbent pads, buffering agents, protein stabilizers, and precision-molded plastic housings. In addition, advanced digital readers and electronic detection modules are increasingly integrated into next-generation products to improve sensitivity and result interpretation accuracy.
Midstream operations involve assay design, reagent formulation, strip assembly, quality control, and automated production line integration. Manufacturers must ensure high batch-to-batch consistency and strict compliance with regulatory standards such as CE marking, FDA clearance, and other regional diagnostic approvals. This is particularly critical given the medical decision-making role of influenza diagnostics in both clinical and public health environments.
Downstream demand spans a wide and diversified customer base, including hospital laboratories, community health centers, public health and disease control agencies, third-party diagnostic laboratories, pharmacies, retail chains, and home self-testing users. Each segment presents distinct requirements in terms of sensitivity, turnaround time, cost structure, and ease of use. Notably, the rapid expansion of home testing and point-of-care diagnostics is reshaping traditional distribution channels and accelerating market decentralization.
In 2024, global production capacity for Influenza A/B antigen detection kits reached approximately 350 million tests, while actual global sales were around 280 million tests. The average selling price stood at approximately USD 4.2 per test, with industry-average gross margins ranging between 60% and 70%, reflecting the high value-added nature of immunodiagnostic technologies and strong demand elasticity during influenza seasons. The market continues to benefit from recurring seasonal demand cycles, making it structurally stable despite short-term fluctuations in outbreak intensity.
From a competitive landscape perspective, the industry is moderately concentrated, with leading global diagnostics companies expanding their portfolios through product innovation, regulatory expansion, and geographic diversification. Key players include BD, Abbott, Quidel, Actim, Denka, Roche, Thermo Fisher Scientific, Meridian Bioscience, Sekisui Diagnostics, Princeton BioMeditech, Access Bio, Response Biomedical, Guangzhou Wondfo Biotech, Jiangsu Bioperfectus Technologies, Hangzhou Biotest Biotech, Wantai BioPharm, Daan Gene, Kehua Bio-Engineering, and Zhuhai Encode Medical Engineering.
Global diagnostics leaders such as Abbott, Roche, Thermo Fisher Scientific, and BD maintain strong competitive positions through extensive R&D capabilities, global regulatory approvals, and broad distribution networks. These companies continue to invest in next-generation point-of-care testing platforms, including digital immunoassays and integrated diagnostic ecosystems that combine hardware, software, and cloud-based epidemiological analytics. Meanwhile, strong regional manufacturers in China have rapidly expanded their global footprint, leveraging cost efficiency, scalable production capacity, and increasing international certification compliance.
In terms of segmentation, the market is categorized into immunochromatography, colloidal gold-based methods, and other advanced detection technologies. Immunochromatography remains the dominant technology due to its simplicity, low cost, and suitability for rapid testing scenarios. However, fluorescent and digital assay formats are gaining increasing adoption in hospital environments and public health programs due to their improved sensitivity and quantitative capabilities.
By application, hospitals represent the largest end-user segment, followed by clinics, home testing, and other institutional users. The hospital segment continues to anchor demand due to high patient throughput and clinical diagnostic requirements. Meanwhile, home testing is emerging as a high-growth segment, driven by rising health awareness, convenience preferences, and post-pandemic behavioral shifts toward self-monitoring of infectious diseases.
The industry is currently undergoing several key structural transformations. First, decentralization of diagnostics is accelerating, shifting testing capabilities from centralized laboratories to point-of-care and home-based environments. Second, digitalization and AI integration are enhancing diagnostic accuracy, result interpretation, and epidemiological tracking. Third, regulatory frameworks are evolving to support rapid approval pathways for emergency and seasonal diagnostic tools, improving market responsiveness during influenza outbreaks.
Looking forward, the Influenza A/B Virus Antigen Detection Kits market is expected to maintain stable growth, supported by recurring seasonal demand, increasing global health preparedness initiatives, and continuous technological innovation in rapid diagnostic platforms. Companies that successfully integrate high-sensitivity detection technologies with scalable manufacturing and digital health ecosystems are likely to strengthen their competitive advantage in this evolving landscape.
Overall, the industry remains a strategically important segment within global infectious disease diagnostics, combining high-volume recurring demand with strong public health relevance.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
